Theory Paper IIIDrNB Cardiology – Theory Notes
ADVANCES IN RESISTANT AND REFRACTORY HYPERTENSION
IDEFINITIONS: RESISTANT VS. REFRACTORY HYPERTENSION
- Resistant Hypertension (RH): Blood pressure (BP) that remains above 130/80 mmHg (or 140/90 mmHg depending on guidelines) despite the concurrent use of three antihypertensive agents of different classes (typically an ACEi/ARB, a Calcium Channel Blocker, and a Diuretic) at maximally tolerated doses.
- Refractory Hypertension: A more severe phenotype in which BP remains uncontrolled despite at least five different antihypertensive agents, including a mineralocorticoid receptor antagonist (MRA) and a long-acting thiazide-like diuretic.
IIPHARMACOLOGICAL ADVANCES
- Non-Steroidal Mineralocorticoid Receptor Antagonists (Finerenone):
- Mechanism: Unlike Spironolactone, Finerenone is non-steroidal and more selective, with a lower risk of gynecomastia.
- Evidence: The FIDELIO-DKD and FIGARO-DKD trials demonstrated cardiorenal protection in type 2 diabetes with CKD, with only modest BP lowering; it is not licensed as an antihypertensive.
- Dual Endothelin Receptor Antagonists (Aprocitentan):
- Mechanism: Inhibits endothelin-1 (blocking both ETA and ETB receptors), a potent vasoconstrictor elevated in resistant hypertension.
- Evidence (PRECISION Trial): Showed that Aprocitentan significantly reduced BP in patients with resistant hypertension when added to standardized background therapy (FDA approved in 2024).
- Aldosterone Synthase Inhibitors (Baxdrostat):
- Mechanism: Directly inhibits the enzyme responsible for aldosterone synthesis rather than blocking the mineralocorticoid receptor.
- Evidence (BrigHTN Trial): Demonstrated dose-dependent reductions in systolic BP in patients with resistant hypertension; the Phase III BaxHTN trial (NEJM 2025) confirmed a placebo-adjusted SBP fall of about 9 to 10 mmHg.
IIIDEVICE-BASED THERAPIES
- Renal Denervation (RDN):
- Technique: Radiofrequency- or ultrasound-based catheter ablation of the sympathetic nerves in the renal arteries.
- Current Status: Following the SPYRAL HTN-ON MED and RADIANCE II trials, RDN is a Class IIb recommendation (ESC 2024) for patients with true resistant hypertension who are intolerant of or fail polypharmacy.
- Carotid Baroreceptor Activation Therapy (BAT):
- Technique: An implanted device (Barostim) that electrically stimulates the carotid baroreceptors, lowering central sympathetic outflow and increasing parasympathetic activity.
- Evidence: Evidence comes mainly from the Rheos Pivotal Trial and registries (BeAT-HF studied heart failure, not hypertension); it is not routinely recommended.
IVSUMMARY OF LANDMARK TRIAL EVIDENCE
| Trial Name | Intervention / Agent | Key Clinical Finding & Status |
|---|---|---|
| PATHWAY-2 | Spironolactone vs. Bisoprolol or Doxazosin | Confirmed Spironolactone as the most effective fourth-line agent for resistant hypertension |
| PRECISION | Aprocitentan (Dual ERA) | Significant BP reduction when added to standardized background therapy in resistant HTN |
| BrigHTN | Baxdrostat (Aldosterone synthase inhibitor) | Dose-dependent systolic BP reduction in resistant hypertension |
| SPYRAL HTN-ON MED & RADIANCE II | Renal Denervation (RDN) (RF & Ultrasound) | Proved the 24-hour “Always-On” BP reduction effect independent of medication adherence |
| SYMPLICITY HTN-3 (Long-Term) | Multi-electrode RF Renal Denervation | Neutral at 6 months, but 36-month follow-up showed larger, durable BP reductions with RDN vs sham |
VTHE INDIAN CLINICAL CONTEXT
- Biochemical Adherence Testing: Biochemical screening (urine or blood testing) for drug adherence is advocated before labeling a patient as having true refractory hypertension.
- High Dietary Salt Sensitivity: Given the high salt intake in the Indian diet, long-acting Chlorthalidone is preferred over Hydrochlorothiazide as the thiazide-like diuretic of choice.
- Role of Renal Denervation: Where long-term drug adherence is compromised by heavy pill burden, RDN is considered in high-risk patients with resistant hypertension.
Key references
- Williams B, MacDonald TM, Morant S, et al. (PATHWAY-2 Investigators): Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2), The Lancet.
- Schlaich MP, Bellet M, Weber MA, et al. (PRECISION Investigators): Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION), The Lancet.
- Freeman MW, Halvorsen YD, Marshall W, et al. (BrigHTN Investigators): Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension, New England Journal of Medicine.
meritmedscript.comDr. Sidhartha Mullapudi
